Revisiting predictors of virologic response to PEGIFN + RBV therapy in HIV-/HCV-coinfected patients: The role of metabolic factors and elevated GGT levels

Journal of Viral Hepatitis

Volumn 21, Issue 1, 2014, Pages 33-41

  Mandorfer, M ^a,b   Reiberger, T ^a,b   Payer, B A ^a,b   Breitenecker, F ^a,b   Aichelburg, M C ^a,b   Obermayer Pietsch, B ^c   Rieger, A ^a,b   Puoti, M ^d,e   Zangerle, R ^f,g   Trauner, M ^a,b   Peck Radosavljevic, M ^a,b  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b Vienna HIV and Liver Study Group   (Austria)

^c MEDICAL UNIVERSITY OF GRAZ   (Austria)

^d OSPEDALE NIGUARDA CA GRANDA   (Italy)

^e AIFA HIV Cohort   (Italy)

^f INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^g AHIVCOS Cohort   (Austria)

Author keywords

glutamyltransferase; hepatitis C virus; human immunodeficiency virus; pegylated interferon; ribavirin

Indexed keywords

CD4 ANTIGEN; GAMMA GLUTAMYLTRANSFERASE; INTERLEUKIN 28B; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PEGINTERFERON ALPHA2A; RIBAVIRIN;

ADULT; ALCOHOL ABUSE; ARTICLE; CD4 LYMPHOCYTE COUNT; CHEMILUMINESCENCE IMMUNOASSAY; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; COHORT ANALYSIS; DRUG TREATMENT FAILURE; FATTY LIVER; FEMALE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; INSULIN RESISTANCE; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSPECTIVE STUDY; TREATMENT DURATION; TREATMENT RESPONSE;

HEPATITIS C VIRUS; HUMAN IMMUNODEFICIENCY VIRUS; PEGYLATED INTERFERON; RIBAVIRIN; Γ-GLUTAMYLTRANSFERASE;

ADULT; DRUG THERAPY, COMBINATION; FEMALE; GAMMA-GLUTAMYLTRANSFERASE; HEPATITIS C, CHRONIC; HIV INFECTIONS; HUMANS; INTERFERON-ALPHA; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; PROGNOSIS; PROSPECTIVE STUDIES; RECOMBINANT PROTEINS; RIBAVIRIN; TREATMENT FAILURE;

EID: 84890566568     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/jvh.12118     Document Type: Article

References (39)

1. Smith C, Sabin CA, Lundgren JD, et al,. Factors associated with specific causes of death amongst HIV-positive individuals in the D:A:D Study. Aids 2010; 24 (10): 1537-1548.
2. Alter MJ,. Epidemiology of viral hepatitis and HIV co-infection. J Hepatol 2006; 44 (1 Suppl): S6-S9. (Pubitemid 43053865)
3. Reiberger T, Ferlitsch A, Sieghart W, et al,. HIV-HCV co-infected patients with low CD4 + cell nadirs are at risk for faster fibrosis progression and portal hypertension. J Viral Hepatitis 2010; 17 (6): 400-409.
4. Graham CS, Baden LR, Yu E, et al,. Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis. Clin Infect Dis 2001; 33 (4): 562-569. (Pubitemid 32709592)
5. Wandeler G, Gsponer T, Bregenzer A, et al,. Hepatitis C virus infections in the Swiss HIV cohort STUDY: a rapidly evolving epidemic. Clin Infect Dis 2012; 55 (10): 1408-1416.
6. Vogel M, Page E, Boesecke C, et al,. Liver fibrosis progression after acute hepatitis C virus infection in HIV-positive individuals. Clin Infect Dis 2012; 54 (4): 556-559.
7. Reiberger T, Obermeier M, Payer BA, et al,. Considerable under-treatment of chronic HCV infection in HIV patients despite acceptable sustained virological response rates in a real-life setting. Antivir Ther 2011; 16 (6): 815-824.
8. Mehta SH, Lucas GM, Mirel LB, et al,. Limited effectiveness of antiviral treatment for hepatitis C in an urban HIV clinic. Aids 2006; 20 (18): 2361-2369. (Pubitemid 44789539)
9. Medrano J, Neukam K, Rallon N, et al,. Modeling the probability of sustained virological response to therapy with pegylated interferon plus ribavirin in patients coinfected with hepatitis C virus and HIV. Clin Infect Dis 2010; 51 (10): 1209-1216.
10. Neukam K, Camacho A, Caruz A, et al,. Prediction of response to pegylated interferon plus ribavirin in HIV/hepatitis C virus (HCV)-coinfected patients using HCV genotype, IL28B variations, and HCV-RNA load. J Hepatol 2012; 56 (4): 788-794.
11. Vachon ML, Factor SH, Branch AD, et al,. Insulin resistance predicts re-treatment failure in an efficacy study of peginterferon-alpha-2a and ribavirin in HIV/HCV co-infected patients. J Hepatol 2011; 54 (1): 41-47.
12. Ryan P, Resino S, Miralles P, et al,. Insulin resistance impairs response to interferon plus ribavirin in patients coinfected with HIV and hepatitis C virus. J Acquir Immune Defic Syndr 2010; 55 (2): 176-181.
13. Cacoub P, Carrat F, Bedossa P, et al,. Insulin resistance impairs sustained virological response rate to pegylated interferon plus ribavirin in HIV-hepatitis C virus-coinfected patients: HOMAVIC-ANRS HC02 Study. Antivir Ther 2009; 14 (6): 839-845.
14. Cesari M, Caramma I, Antinori S, Adorni F, Galli M, Milazzo L,. Impact of hyperglycaemia and cholesterol levels on the outcome of hepatitis C virus (HCV) treatment in HIV/HCV-coinfected patients. HIV Med 2009; 10 (9): 580-585.
15. Butt AA, Umbleja T, Andersen JW, Sherman KE, Chung RT,. Impact of peginterferon alpha and ribavirin treatment on lipid profiles and insulin resistance in hepatitis C virus/HIV-coinfected persons: the AIDS clinical trials group A5178 study. Clin Infect Dis 2012; 55 (5): 631-638.
16. Merchante N, de los Santos-Gil I, Merino D, et al,. Insulin resistance is not a relevant predictor of sustained virological response to pegylated interferon plus ribavirin in HIV/HCV co-infected patients. J Hepatol 2009; 50 (4): 684-692.
17. Eslam M, Lopez-Cortes LF, Romero-Gomez M,. The role of insulin resistance in HIV/hepatitis C virus-coinfected patients. Curr Opin HIV AIDS 2011; 6 (6): 553-558.
18. Opravil M, Sasadeusz J, Cooper DA, et al,. Effect of baseline CD4 cell count on the efficacy and safety of peginterferon Alfa-2a (40KD) plus ribavirin in patients with HIV/hepatitis C virus coinfection. J Acquir Immune Defic Syndr 2008; 47 (1): 36-49. (Pubitemid 351619367)
19. Pineda JA, Mira JA, Gil Ide L, et al,. Influence of concomitant antiretroviral therapy on the rate of sustained virological response to pegylated interferon plus ribavirin in hepatitis C virus/HIV-coinfected patients. J antimicrob chemother 2007; 60 (6): 1347-1354. (Pubitemid 350168332)
20. Grasso A, Malfatti F, De Leo P, et al,. Insulin resistance predicts rapid virological response in non-diabetic, non-cirrhotic genotype 1 HCV patients treated with peginterferon alpha-2b plus ribavirin. J Hepatol 2009; 51 (6): 984-990.
21. Mauss S, Hueppe D, John C, et al,. Estimating the likelihood of sustained virological response in chronic hepatitis C therapy. J Viral Hepat 2011; 18 (4): e81-e90.
22. Fernandez-Rodriguez CM, Alonso S, Martinez SM, et al,. Peginterferon plus ribavirin and sustained virological response in HCV-related cirrhosis: outcomes and factors predicting response. Am J Gastroenterol 2010; 105 (10): 2164-2172; quiz 73.
23. Bergmann JF, Vrolijk JM, van der Schaar P, et al,. Gamma- glutamyltransferase and rapid virological response as predictors of successful treatment with experimental or standard peginterferon-alpha-2b in chronic hepatitis C non-responders. Liver Int 2007; 27 (9): 1217-1225. (Pubitemid 47543150)
24. Villela-Nogueira CA, Perez RM, De Segadas Soares JA, Coelho HS,. Gamma-glutamyl transferase (GGT) as an independent predictive factor of sustained virologic response in patients with hepatitis C treated with interferon-alpha and ribavirin. J Clin Gastroenterol 2005; 39 (8): 728-730. (Pubitemid 41177095)
25. Weich V, Herrmann E, Chung TL, et al,. The determination of GGT is the most reliable predictor of nonresponsiveness to interferon-alpha based therapy in HCV type-1 infection. J Gastroenterol 2011; 46 (12): 1427-1436.
26. Payer BA, Reiberger T, Aberle J, et al,. IL28B and interferon-gamma inducible protein 10 for prediction of rapid virologic response and sustained virologic response in HIV-HCV-coinfected patients. Eur J Clin Invest 2011; 42 (6): 599-606.
27. Reiberger T, Payer BA, Ferlitsch A, et al,. A prospective evaluation of pulmonary, systemic and hepatic hemodynamics in HIV-HCV coinfected patients prior and after antiviral therapy with pegylated interferon and ribavirin. Antivir Ther 2012; 17 (7): 1327-1334.
28. Berenguer J, Alvarez-Pellicer J, Martin PM, et al,. Sustained virological response to interferon plus ribavirin reduces liver-related complications and mortality in patients coinfected with human immunodeficiency virus and hepatitis C virus. Hepatology 2009; 50 (2): 407-413.
29. Mandorfer M, Reiberger T, Payer BA, et al,. Low vitamin D levels are associated with impaired virologic response to PEGIFN + RBV therapy in HIV-hepatitis C virus coinfected patients. Aids 2013; 27 (2): 227-232.
30. Zeuzem S, Rodriguez-Torres M, Rajender Reddy K, et al,. Optimized threshold for serum HCV RNA to predict treatment outcomes in hepatitis C patients receiving peginterferon alfa-2a/ribavirin. J Viral Hepat 2012; 19 (11): 766-774.
31. Everhart JE, Wright EC,. Association of gamma-glutamyltransferase (GGT) activity with treatment and clinical outcomes in chronic hepatitis C (HCV). Hepatology 2012; 57 (5): 1725-1733.
32. Agundez JA, Garcia-Martin E, Maestro ML, et al,. Relation of IL28B gene polymorphism with biochemical and histological features in hepatitis C virus-induced liver disease. PLoS ONE 2012; 7 (5): e37998.
33. Conigrave KM, Davies P, Haber P, Whitfield JB,. Traditional markers of excessive alcohol use. Addiction 2003; 98 (Suppl 2): 31-43. (Pubitemid 38030760)
34. Choudhury SR, Ueshima H, Kita Y, et al,. Alcohol intake and serum lipids in a Japanese population. Int J Epidemiol 1994; 23 (5): 940-947. (Pubitemid 24331208)
35. Berenguer J, Rodriguez E, Miralles P, et al,. Sustained virological response to interferon plus ribavirin reduces non-liver-related mortality in patients coinfected with HIV and Hepatitis C virus. Clin Infect Dis 2012; 55 (5): 728-736.
36. Nunez M,. Clinical syndromes and consequences of antiretroviral-related hepatotoxicity. Hepatology 2010; 52 (3): 1143-1155.
37. Stattermayer AF, Rutter K, Beinhardt S, et al,. Association of the IL28B genotype with insulin resistance in patients with chronic hepatitis C. J Hepatol 2012; 57 (3): 492-498.
38. Hull MW, Rollet K, Odueyungbo A, et al,. Factors associated with discordance between absolute CD4 cell count and CD4 cell percentage in patients coinfected with HIV and hepatitis C virus. Clin Infect Dis 2012; 54 (12): 1798-1805.
39. Mandorfer M, Reiberger T, Payer BA, Peck-Radosavljevic M,. The Influence of Portal Pressure on the Discordance Between Absolute CD4 + Cell Count and CD4 + Cell Percentage in HIV/Hepatitis C Virus-Coinfected Patients. Clin Infect Dis 2012; 56 (6): 904-905.